Discover
TSVT
2seventy bio, Inc.
5.00
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 70.07% | |
| 1y | 14.16% |
5.00
day range
5.00
52 week range
| Open | 5.00 | Prev Close | 5.00 | Low | 5.00 | High | 5.00 | Mkt Cap | N/A |
| Vol | 1.16M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -6.95 |
| Beta | 1.79 | Short Ratio | 14.47 | Inst. Own | 90.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 6.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.14 | -0.18 | -0.04 | -28.57% |
| 2024-08-07 | 2024-06 | -0.35 | N/A | N/A | N/A |
| 2024-08-07 | 2024-06 | -0.35 | -0.29 | 0.06 | 17.14% |
| 2024-05-08 | 2024-03 | -0.72 | N/A | N/A | N/A |
| 2024-05-08 | 2024-03 | -0.72 | -0.81 | -0.09 | -12.50% |
| 2024-03-05 | 2023-12 | -1.22 | -1.11 | 0.11 | 9.02% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-07-29 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2024-06-27 | Wedbush | Upgrade | Neutral | Neutral |
| 2024-05-09 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2024-04-08 | Citigroup | Upgrade | Buy | Buy |
| 2024-03-18 | Wedbush | Upgrade | Neutral | Neutral |
| 2024-01-31 | Leerink Partners | Upgrade | Market Perform | Outperform |
Profile
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-06-30 | BAIRD WILLIAM D III | Chief Executive Officer | 894.61K | Stock Award(Grant) |
| 2024-06-09 | CASDIN CAPITAL, LLC | Unknown | 0.00 | Stock Award(Grant) |
| 2024-10-02 | EATWELL VICTORIA | Chief Financial Officer | 340.09K | Sale |
| 2024-06-09 | GLICKMAN SARAH JS | Director | 27.65K | Stock Award(Grant) |
| 2024-01-07 | GREGORY PHILIP D | Officer | 310.28K | Stock Award(Grant) |
| 2024-06-09 | LIN WEI | Director | 32.85K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Kynam Capital Management, LP | 5.95M | 17.80M | 11.54% |
| 2024-09-29 | Goldman Sachs Group Inc | 4.22M | 12.62M | 8.18% |
| 2024-09-29 | Blackrock Inc. | 3.87M | 11.57M | 7.50% |
| 2024-09-29 | Vanguard Group Inc | 3.77M | 11.28M | 7.31% |
| 2024-09-29 | Morgan Stanley | 2.89M | 8.65M | 5.61% |
| 2024-09-29 | Madison Avenue Partners, LP | 2.56M | 7.66M | 4.97% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.54M | 4.61M | 2.99% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.29M | 3.87M | 2.51% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 780.36K | 2.33M | 1.51% |
| 2024-09-29 | Vanguard Strategic Equity Fund | 702.79K | 2.10M | 1.36% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 499.37K | 1.49M | 0.97% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 483.44K | 1.45M | 0.94% |